Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · October 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06562907). This is a study registration, not published results. Lead sponsor: Gilead Sciences. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 134 participants (ESTIMATED). Conditions: Weight Management. Interventions: DRUG: GS-4571; DRUG: Placebo; DRUG: Omeprazole. Primary outcome measures: Single-Dose PK Parameter AUCinf of GS-4571 , Up to 96 hours postdose; Single-Dose PK Parameter Cmax of GS-4571 , Up to 96 hours postdose; Multiple-Dose Plasma PK Parameter: AUCtau of GS-4571 , Up to 96 hours postdose; Multiple-Dose Plasma PK Parameter: Cmax of GS-4571 , Up to 96 hours postdose; Percentage of Participants of Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), or Deaths , Day 1 up to 95 days; Percentage of Participants of Treatment-Emergent Laboratory Abnormalities , Day 1 up to 95 days. Brief summary: The goal of this clinical study is to learn more about the study drug, GS-4571, and how safe it is in 3 groups, i) Healthy participants, ii) Healthy non-diabetic obese participants, and iii) Non-obese participants with Type 2 Diabetes Mellitus (T2DM). The primary objectives of this study are: * To characterize the pharmacokinetics (PK) of GS-4571 following single and multiple ascending oral doses of GS-4571. * To evaluate the effect of concomitant food intake and (if conducted) a representative acid-reducing agent (proton pump inhibitor (PPI), omeprazole) on the PK of GS-4571. * To evaluate the safety and tolerability of single and multiple ascending oral doses of GS-4571.